PRTC vs. PRAX, PHAR, SVRA, YMAB, BCYC, AVTE, LBPH, NRIX, IRON, and AUPH
Should you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Praxis Precision Medicines (PRAX), Pharming Group (PHAR), Savara (SVRA), Y-mAbs Therapeutics (YMAB), Bicycle Therapeutics (BCYC), Aerovate Therapeutics (AVTE), Longboard Pharmaceuticals (LBPH), Nurix Therapeutics (NRIX), Disc Medicine (IRON), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical preparations" industry.
PureTech Health (NASDAQ:PRTC) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, community ranking, risk and dividends.
Praxis Precision Medicines has a consensus target price of $103.00, indicating a potential upside of 87.14%. Given Praxis Precision Medicines' higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than PureTech Health.
PureTech Health has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.89, suggesting that its stock price is 189% more volatile than the S&P 500.
PureTech Health has a net margin of 0.00% compared to Praxis Precision Medicines' net margin of -5,037.88%. PureTech Health's return on equity of 0.00% beat Praxis Precision Medicines' return on equity.
PureTech Health has higher revenue and earnings than Praxis Precision Medicines.
0.0% of PureTech Health shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Praxis Precision Medicines received 15 more outperform votes than PureTech Health when rated by MarketBeat users. Likewise, 59.46% of users gave Praxis Precision Medicines an outperform vote while only 38.89% of users gave PureTech Health an outperform vote.
In the previous week, Praxis Precision Medicines had 5 more articles in the media than PureTech Health. MarketBeat recorded 7 mentions for Praxis Precision Medicines and 2 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.53 beat Praxis Precision Medicines' score of 0.29 indicating that PureTech Health is being referred to more favorably in the media.
Summary
Praxis Precision Medicines beats PureTech Health on 8 of the 15 factors compared between the two stocks.
Get PureTech Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PureTech Health Competitors List
Related Companies and Tools
